Predicting risk severity and response of fetal neonatal alloimmune thrombocytopenia

Ophira Salomon*, Nurit Rosenberg

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations


Fetal neonatal alloimmune thrombocytopenia (FNAIT) is a devastating bleeding disorder in the fetus or neonate caused by transplacental transport of maternal alloantibodies to paternal-derived antigen on fetal platelets. In Caucasians, up to 80% of FNAIT cases result from maternal immunization to human platelet antigen (HPA)-1a. New methods have developed facilitating detection of common and private antibodies against HPAs triggering FNAIT. Understanding the pathogenesis of FNAIT made it possible to develop a novel strategy to treat this disorder. To date, recombinant monoclonal antibodies directed against the β3 integrin and Fc receptors have been tested in a mouse model of FNAIT, and seem to be promising. Whether those novel treatments will eventually replace the conventional high dose immunoglobulin G in women with FNAIT is yet unknown.

Original languageEnglish
Pages (from-to)304-312
Number of pages9
JournalBritish Journal of Haematology
Issue number3
StatePublished - Aug 2013
Externally publishedYes


  • Fetal blood sampling
  • Human platelet antibodies
  • Human platelet antigen
  • Intracranial haemorrhage
  • Neonatal alloimmune thrombocytopenia


Dive into the research topics of 'Predicting risk severity and response of fetal neonatal alloimmune thrombocytopenia'. Together they form a unique fingerprint.

Cite this